|
Jul 30
|
Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference
|
|
May 2
|
Aileron reports data from Cohort 1 of Phase Ib inhaled IPF treatment trial
|
|
May 1
|
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million
|
|
May 1
|
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
|